a b s t r a c t PERFORM-K was a cross-sectional observational study that investigated functional disability, productivity and quality of life in MDD outpatients in South Korea, and the associations of these with depressive symptoms, perceived cognitive dysfunction and other factors. A total of 312 outpatients who started antidepressant monotherapy underwent a single study interview. Physicians and patients assessed depression severity. Patients also assessed: perceived cognitive dysfunction, functional disability, impaired productivity and quality of life. Patients had moderate to severe depression (MADRS mean total score: 28.9 77.3), and reported marked functional disability (SDS mean total score: 16.77 8.6), impaired productivity (WPAI mean overall work productivity loss: 52.4 7 31.8%), perceived cognitive dysfunction (PDQ-D mean total score: 29.9 7 18.6) and impaired quality of life (EQ-5D mean utility index score of 0.726 70.192). Greater functional disability and impairment in daily activities were associated with more severe depression and greater perceived cognitive dysfunction. Irrespective of depression severity, patients with more severe perceived cognitive dysfunction reported worse work-related productivity outcomes (higher presenteeism and greater overall work productivity loss). PERFORM-K confirms the impact of MDD on functional status and well-being in South Korean patients, and highlights the importance of recognising cognitive dysfunction in clinical practice.
Introduction
Depressive disorders including major depressive disorder (MDD) have consistently been reported as being amongst the leading causes of disability worldwide in the Global Burden of Disease studies by the World Health Organisation (Ferrari et al., 2013) . The average lifetime prevalence of MDD is estimated at 14.6% for high income countries (Kessler and Bromet, 2013) ; in South Korea, the lifetime prevalence is estimated at 6.7%, which has increased by 0.2% annually over the past decade (Jeon, 2012) .
MDD is characterized by physical, cognitive and emotional symptoms that affect patient functioning and quality of life (Hammar and Ardal, 2009; Langlieb and Guico-Pabia, 2010; Ferrari et al., 2013) . Several studies have identified an association between depression severity and functional impairment (Kennedy et al., 2002; Srisurapanont et al., 2013) , and report the long-term negative impact of depression on work performance, social adjustment, engagement in leisure activities and family relationships (Tweed, 1993; Kennedy and Paykel, 2004; Greer et al., 2010; Conradi et al., 2011) . Apart from the emotional burden, the loss of work productivity and impaired work performance associated with MDD result in a substantial economic burden -in 2005, the total cost of depression in South Korea was estimated at $4.05 billion, with indirect costs attributable to lost workplace productivity ($2.96 billion) far exceeding medical costs ($152.6 million) (Chang et al., 2012) .
Cognitive dysfunction is gaining attention as one of the key determinants of functional disability in MDD patients (Hammar and Ardal, 2009; Conradi et al., 2011; McIntyre et al., 2013) . In MDD, the most commonly impaired cognitive domains are: attention, memory, executive function and processing speed (Millan et al., 2012) . Some cognitive dysfunction may persist beyond Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/psychres clinical symptom remission (Conradi et al., 2011) , and has been suggested to impact work function and lead to poor occupational outcomes (Adler et al., 2006; Israel, 2006) . With increased recognition of the debilitating impact of MDD symptoms on patient functioning, the goal of MDD treatment now goes beyond achieving clinical remission to include recovery of functional status (Greer et al., 2010) .
Several studies have investigated the burden of MDD in South Korea and described the impact of depression on patients' ability to work, lost productive time and their quality of life Woo et al., 2011; Oh et al., 2013; Sohn et al., 2013) . However, no study has to date been conducted to specifically examine the impact of cognitive symptoms of MDD patients on their functional disability and work impairment in South Korea. The objective of this study was to investigate the functional disability, work productivity and quality of life of MDD outpatients in South Korea, and the association with depressive symptoms, perceived cognitive dysfunction and other factors.
Methods

PERFORM-K (Epidemiological
Research on Functioning Outcomes Related to Major depressive disorder in South Korea) was an observational, cross-sectional, multi-site study.
Study participants
Patients were recruited from 29 psychiatric departments in university or general hospitals throughout South Korea from October 2013 to January 2014. Eligible patients were outpatients between 19 and 65 years old with a diagnosis of MDD according to the DSM-IV, confirmed by the Mini-International Neuropsychiatric Interview (Sheehan et al., 1998) , and started on antidepressant monotherapy either as first-line therapy or as first treatment switch from previous antidepressant monotherapy. Patients were excluded if they: had a diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, substance dependence, dementia or other neurodegenerative diseases that affect cognitive functioning, or a mood disorder due to general medical conditions or substances; were acutely suicidal; were pregnant, breastfeeding or 6 months post-partum; were unable to read or understand the information sheet, informed consent form or patient-reported questionnaires; or were concurrently participating in another clinical trial. Based on the above inclusion and exclusion criteria, patients attending psychiatric departments of the study hospitals were recruited consecutively if they agreed to participate.
Antidepressant treatment was not determined in advance by the study protocol and treatment was clearly separated from the decision to include the patient in the study. All eligible patients had given written informed consent. The study was approved by the institutional review boards of all participating hospitals.
Study design and study assessments
Study participants underwent a single interview during a routine visit by the patient in the normal course of care when a new antidepressant was initiated as monotherapy. Patient information collected during the study visit included socio-demographic data, physical characteristics and past medical history.
Depression severity was measured using both physician-rated assessments and patient-reported outcome (PRO) instruments. Physicians assessed depression severity using the Clinical Global Impressions -Severity of Illness scale (CGI-S) and the Montgomery-Åsberg Depression Rating Scale (MADRS). CGI-S is a standardised, generic assessment tool for rating the severity of an illness on a 7-point scale (with 1 indicating normal health and 7 indicating extreme illness) (Guy, 1976) . The MADRS consists of 10 items, with each item rated from 0 (normal findings or absence of symptoms) to 6 (severe depressive symptoms) adding up to a total score of 60 (Montgomery and Asberg, 1979) . The following pre-defined MADRS categories often used in clinical trials (Raison et al., 2007; Bose et al., 2012) and considered to be representative of depression severity were used in this study: "in remission or mild depression" (0-25), "moderate depression" (26-29), "severe depression" (30-34) and "very severe depression" (35-60). Patients also assessed depression severity using the 9-item Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001) . A total score ranging from 0 (absence of depression) to 27 (severe depression) is calculated, with depression severity categorised as "in remission" (total score r4), "minimal symptoms" (5-9), "mild depression" (10-14), "moderately severe depression" (15-19) and "severe depression" (20-27) .
Cognitive dysfunction was assessed using the Perceived Deficits Questionnaire for Depression (PDQ-D) (Sullivan et al., 1990) . The self-reported, 20-item instrument assesses four sub-scales: attention/concentration, retrospective memory, prospective memory and planning/organisation. Each item is rated on a 0-4 scale, with a total score of 20 for each of the sub-scales. As there is no known threshold to define severity of perceived cognitive dysfunction, categories were defined as distribution-based quartiles with higher scores indicating worse perceived cognitive dysfunction.
In our study 'functioning outcomes' referred to functional disability and work-or activity-related productivity. The Sheehan Disability Scale (SDS) was used to assess functional disability over the previous 7 days in 3 domains: work/school, social life/leisure activities and family life/home duties (Sheehan et al., 1996) . Patients rated the severity of impairment in each domain on a scale of 0-10; a total functional impairment score was computed ranging from 0 (unimpaired) to 30 (highly impaired). "Marked disruption" was defined as an SDS score of at least 7 in a domain.
The Work Productivity and Activity Impairment, Specific Health Problems questionnaire (WPAI) is a self-administered instrument that was used to measure impairment in productivity related to work and regular, daily activities (such as household work, childcare, shopping, exercising or studying) (Reilly et al., 1993) . Productivity is assessed on a 10-point scale with higher scores indicative of worse work productivity or activity impairment. Scores are multiplied by 100 and reported in the following indexes: absenteeism (percent of work time missed due to MDD), presenteeism (percent impairment while working due to MDD), overall work productivity loss (a composite measure of both presenteeism and absenteeism) and activity impairment (degree of impairment of regular, non-work activities due to MDD).
Quality of life was measured by the EuroQOL Five Dimensions (EQ-5D) questionnaire. Patients rated severity levels ("no problems", "some problems" or "extreme problems") for each of the five health dimensions (mobility, self-care, usual activities, pain/ discomfort and depression/anxiety). A utility index score was derived, wherein "1" indicated perfect health, "0" indicated a state of death and scores below 0 indicated a state worse than death. Patients also assessed their health state with a visual analogue scale that ranged between 0 (worst imaginable health state) and 100 (best imaginable health state) (EuroQol Group, 1990 ).
Statistical analysis
The population for analysis comprised all eligible patients who completed at least one of the PRO assessments. All assessment data were summarised from the single study visit using descriptive techniques. Unless otherwise specified, continuous variables are presented as the number of observations and mean 7standard deviation (SD); categorical and binary variables are presented as counts and percentages.
Functional disability (mean total SDS score), productivity (WPAI mean sub-scores) and quality of life (EQ-5D mean utility index score) were compared between patient groups defined by depression severity (MADRS) and severity of perceived cognitive dysfunction (PDQ-D).
MADRS items were compared between patient groups defined by severity of perceived cognitive dysfunction (PDQ-D) using oneway analyses of variance (ANOVA).
1 Correlations between MADRS and PDQ-D were calculated using Pearson's and Spearman's correlation coefficients.
To determine factors associated with functional disability (SDS), productivity (WPAI) and quality of life (EQ-5D), a two-step statistical analysis was performed. SDS total score, WPAI subscores and EQ-5D utility index score were compared between patient groups by means of one-way ANOVA.
2 SDS total score, WPAI sub-scores and EQ-5D utility index score were then each evaluated using analyses of co-variance (ANCOVA) with region, age, gender and MADRS categories as forced factors and the following as co-factors and covariates (added to the model if their p-value was lower than 0.10 in the univariate analyses): educational level, presence of anxiety symptom or disorder, presence of chronic medical condition, presence of chronic pain or fibromyalgia, recurrence of depression episode, time of previous depression episode, history of suicide attempt, history of sick leave in the previous 12 months, history of hospitalisation, time since beginning of current major depressive episode, switch of treatment at study inclusion, depression severity as assessed by CGI-S and severity of perceived cognitive dysfunction as assessed by PDQ-D. Statistical tests were two-sided at a 5% significance level. Imputation of missing data was not used in any of the analyses (i.e. all data were observed cases). Analyses were performed using the SAS s statistical software (SAS Institute, Cary, NC, USA), Version 9.2.
Results
The study enroled 343 patients, 31 of whom were excluded from the analyzable population ( Fig. 1) .
Demographic data and clinical characteristics
Patients had a mean age of 45.2 713.1 years, most were women (74.0%), had received formal education until at least high school (73.1%), and generally lived in urban areas of South Korea (83.3%). Similar proportions of patients were employed or not employed (41.7% versus 38.5%, respectively); the remaining patients comprised a non-working population that included students and retirees (Table 1) .
The majority of patients were newly diagnosed with MDD (59.6%). Over half of the patients (55.4%) presented with clinically significant symptoms of anxiety. Antidepressant treatment was initiated as first-line monotherapy in 77.2% of patients at the study visit, while the remaining 22.8% of patients (n ¼71) had previously been treated with an antidepressant and were switching therapy. The main reason for switching treatment was lack of efficacy of the previous antidepressant therapy (78.6%) ( Table 1) . Patients were rated by physicians as having moderate to severe depression, with a MADRS mean total score of 28.9 77.3. Patients' self-reported levels of depression severity were consistent with physician-rated levels of depression severity, with 62.3% reporting a PHQ-9 score between 15 and 27 (moderate to severe depression).
Although there are no pre-defined categories for the severity of perceived cognitive dysfunction, patients reported a PDQ-D mean total score of 29.9 718.6, which fell in the third quartile of the PDQ-D score distribution (first quartile: 0-12; second quartile: 13-27; third quartile: 28-43; fourth quartile: 44-80) ( Table 1) . PDQ-D scores for the individual dimensions were: 8.5 75.3 for attention/ concentration, 6.1 75.1 for retrospective memory, 6.4 74.6 for prospective memory and 8.9 75.6 for planning/organisation.
All items in the MADRS were significantly associated with more severe perceived cognitive dysfunction (p ¼0.004 for "reduced appetite"; p o0.001 for all other MADRS items), except "reduced sleep" (p ¼ 0.394). Pearson and Spearman correlation coefficients between MADRS and PDQ-D scores were 0.41 and 0.42 respectively.
Functioning outcomes and quality of life
Patients reported the following mean SDS scores in the respective domains: 5.7 73.2 for work/school, 5.6 73.1 for family life/home duties and 5.4 73.3 for social life/leisure activities. A similar proportion of patients reported 'marked disruption' across all three SDS domains (Table 2 ). Higher levels of functional disability (defined by SDS) were reported in patients with more severe depression (Fig. 2a) and those with more severe perceived cognitive dysfunction (Fig. 2b) . 1 MADRS items included: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts.
2 Patient groups were defined by the following variables: region, age, gender, educational level, presence of anxiety symptom or disorder, presence of chronic medical condition, presence of chronic pain or fibromyalgia, presence of sleep disorders, recurrence of depression episode, history of sick leave in the past 12 months, history of hospitalisation, history of suicide attempt, time of previous depressive episode, time since beginning of this depressive episode, switch of treatment at study inclusion, severity of depression as assessed by PHQ-9, MADRS and CGI-S, and severity of perceived cognitive dysfunction as assessed by PDQ-D. Additional variables considered in the analysis of EQ-5D were: presence of an important family event and presence of an important professional event.
The majority of patients reported an overall work productivity loss of 52.4% in the last 7 days, with 20% of work time missed (absenteeism) and 47.1% of actual work impaired (presenteeism) due to MDD (Table 2) . Similarly, 57.9% of patients' regular, daily activities were impaired due to MDD. Productivity as assessed by each domain of WPAI was more impaired with greater depression severity (Fig. 3a) and greater perceived cognitive dysfunction (Fig. 3b) .
The EQ-5D mean utility index score reflecting patients' assessment of their quality of life was 0.726 70.192. Quality of life was lower in patients with greater depression severity (Fig. 4a) and greater perceived cognitive dysfunction (Fig. 4b) .
Factors associated with functioning outcomes and quality of life
Based on univariate analyses, greater functional disability, higher work impairment and poorer quality of life were all associated with more severe depression as measured by MADRS (p o0.001 for the association with functional disability; p o0.01 for absenteeism, p o0.001 for all other WPAI scores and p o0.001 for quality of life). They were also all associated with more severe perceived cognitive dysfunction (p o0.001 for the association with functional disability; p o0.05 for absenteeism, p o0.001 for all other WPAI scores and p o0.001 for quality of life).
In the multivariate analysis models (Table 3) , greater functional disability (SDS) remained associated with more severe depression (MADRS) and perceived cognitive dysfunction (PDQ-D). Additionally, b WPAI sub-scales were only assessed in working patients, where "work" referred to paid work. It should be noted that the SDS "work/school" domain was assessed in both working and non-working patients, where "work" included both paid and non-paid work, such as housework, volunteer work or work done at home.
the following factors were also associated with greater functional disability: younger age, regions in South Korea outside of Seoul, and a history of sick leave within the previous 12 months. Greater activity impairment (WPAI) was associated with younger patients, more severe depression (MADRS) and more severe perceived cognitive dysfunction (PDQ-D) (Table 3) . Greater overall work productivity loss (WPAI) was associated with gender (men had more impairment than women), the presence of at least one anxiety disorder and more severe perceived cognitive dysfunction. Higher absenteeism was associated with a switch of antidepressant at the study visit, the presence of at least one chronic comorbid medical condition and a history of sick leave within the previous 12 months. More severe perceived cognitive dysfunction was the only factor significantly associated with higher presenteeism.
Poorer quality of life was associated with a history of sick leave within the previous 12 months, the presence of chronic pain or fibromyalgia, more severe depression (MADRS) and more severe perceived cognitive dysfunction (PDQ-D) (Table 3) .
Discussion
This study describes the burden of MDD on patients in South Korea initiating or switching antidepressant monotherapy. Patients in the study reported marked disruption across all domains of functioning (social, work and family). Greater functional disability, greater impairment in daily activities and worse quality of life were associated with more severe depression and worse perceived cognitive dysfunction. In addition, irrespective of depression severity, employed patients who reported more severe cognitive dysfunction also reported worse work-related productivity outcomes.
The level of functional disability, as measured by the SDS in our study (with nearly half of the study population reporting marked impairment in work, social and family activities), was comparable to that observed in the cross-sectional, observational Study of Aspects of Asian Depression (SAAD) (Srisurapanont et al., 2013) . Similar to PERFORM-K, the SAAD also found that MDD had the greatest impact on the work/school domain, although there were markedly smaller differences between each domain in PERFORM-K than in SAAD. These results differ from an observational study in the USA, which reported greater impairment in social/leisure activities than in work/school or family/home activities (Kennedy et al., 2002) , perhaps reflecting differences between the impact of MDD on Asian and US societies.
Similar levels of impairment were reported in the study for overall work productivity and daily activities (52% and 58% respectively), which were also consistent with reports from a comparable European study (PERFORM) (Saragoussi et al. manuscript in preparation). Our study also confirms previous findings that presenteeism is a greater problem than absenteeism in patients with MDD (Stewart et al., 2003; Sanderson and Andrews, 2006) . Patients in PERFORM-K reported an average of 20% work time missed due to MDD (absenteeism), corresponding to a loss of approximately 10 h in the 7 days preceding the study visit. Even when patients were present at work (35 h in the week prior to the study interview), almost half of their time was deemed unproductive (presenteeism). PERFORM reported a similar presenteeism index but a higher absenteeism index (Saragoussi et al. manuscript in preparation), potentially suggesting different work cultures: patients in South Korea may face greater pressure not to take leave due to illness compared to patients in Europe. MDDrelated work impairment is associated with substantial costs: in a Korean study, lost productive time accounted for 33.4% of the working patient's average annual salary, with presenteeism cost (USD 6429) exceeding absenteeism cost (USD 3680) (Woo et al., 2011) .
The findings that greater functional disability and impairment in daily activities were associated with greater depression severity and worse perceived cognitive dysfunction, even when other factors were accounted for in the multivariate analyses, were consistent with the European PERFORM study (Haro et al., 2013) . In both studies, functional disability was also correlated with other factors, including country and antidepressant therapy switch at study entry in PERFORM, and region (non-Seoul areas of South Korea), younger patients and a history of taking sick leave in PERFORM-K.
Factors associated with work-related outcomes were more varied. Severity of depression as assessed by the MADRS was not significantly associated with any work outcome (although the association with presenteeism at p ¼0.059 was close to the threshold of significance). On the other hand, more severe perceived cognitive dysfunction (PDQ-D) was associated with greater overall work productivity loss and higher presenteeism.
Greater overall work productivity loss was associated with being male, greater perceived cognitive dysfunction and the presence of at least one anxiety symptom or disorder. Ours and a Japanese study have shown that men report greater work productivity loss due to emotional disorders when compared to women (Wada et al., 2013) . This may reflect traditional gender role expectations for Asian men, such as emotional restraint, leading to delayed help-seeking (Oliver et al., 2005; Lindinger-Sternart, 2015; Yu et al., 2015) and potentially more severe work disability. As anxiety and depression are commonly comorbid with each other (Hirschfeld, 2001 ), anxiety appears to play a key role in work productivity impairment and should therefore be considered carefully by clinicians when managing MDD patients.
Higher absenteeism was associated with a switch in antidepressant treatment at the study visit, presence of at least one chronic comorbid medical condition (suggesting that sick leave may have been taken for a patient's other medical conditions) and a history of sick leave within the past year, which highlights the recurrent nature of sick leave.
Patients' perception of health status and quality of life, measured by the EQ-5D, were not as impaired as in other studies (Woo et al., 2014; Novick et al., 2015) . Patients who reported a lower quality of life had more severe depression (MADRS), greater perceived cognitive dysfunction (PDQ-D), chronic pain or fibromyalgia, and a history of sick leave within the past year. Chronic pain is itself associated with poor quality of life, with fibromyalgia having one of the lowest EQ-5D scores compared to other conditions with chronic pain (Picavet and Hoeymans, 2004) . However, only a small proportion of patients in PERFORM-K reported chronic pain and fibromyalgia (5.4% and 0.3% respectively); thus the EQ-5D scores in PERFORM-K primarily reflect the impact of MDD on patients' perceived quality of life.
In our study, perceived cognitive dysfunction was not associated with absenteeism, but was the only factor associated with presenteeism when all other factors were controlled for in multivariate analyses. A previous study reported that impairment in cognitive function, such as in decision-making, contributes to lower performance at work (Lerner et al., 2004) ; this may explain why cognitive dysfunction was associated with presenteeism in PERFORM-K. The substantial impact of MDD on presenteeism identified in our study emphasises the importance of assessing cognitive dysfunction in MDD patients. This is particularly so in light of studies that have reported the persistence of cognitive dysfunction in the remission phase of depression (Weiland-Fiedler et al., 2004; Hammar and Ardal, 2009) , resulting in impaired social and occupational functioning (Papakostas and Culpepper, 2015) .
PERFORM-K is the first non-interventional study in Asia to describe cognitive dysfunction in MDD patients. Perceived cognitive dysfunction was assessed using PDQ-D, a 20-item questionnaire adapted from the PDQ scale for multiple sclerosis and validated in depression (Fehnel et al., 2013; Lam et al., 2013) , including in a South Korean population (Kim et al. 2016 ). In our study, impairment was comparable to that of depressed US patients with cognitive dysfunction, and greater than that of depressed patients without cognitive dysfunction and of non-depressed populations in the US and UK (Lundbeck data on file). The present study also confirmed the results of previous studies which reported a predominance of cognitive impairment in the domains of planning/organisation and concentration/attention over that in the memory domain (Lam et al., 2013) .
Recent research has shown that depression severity may be a predictor of subjective cognitive dysfunction (Misdowiak et al., 2012) . However our and a previous study (Fava et al., 2009) show only a weak correlation between depression severity and perceived cognitive dysfunction, suggesting that tools used to assess perceived cognitive dysfunction may measure a different aspect of depression than those used to measure depression severity. Considering that in our study perceived cognitive dysfunction was associated with work-related outcomes, while severity of depression was not, clinicians should assess cognitive dysfunction in their daily practice, in addition to assessing the severity of depressive symptoms.
The present study has a number of strengths. Patients were recruited from tertiary centres across South Korea, thereby reflecting the socio-demographics and clinical profile of patients across the country, similar to that of a large, national, South Korean cohort MDD study (CRESCEND) . The cross-sectional, observational methodology was useful for gaining a better understanding of real-life clinical practice, although causal inferences that could be drawn from the study results were limited due to uncontrollable confounding factors, selection bias or reverse causality. The use of PROs allowed us to a) b) gather information not captured in physician-rated instruments, namely, the patient's perspective of living with MDD and its impact on their lives.
A potential limitation of the study, however, was the assessment of cognitive dysfunction using the PDQ-D, which is an assessment of subjective (perceived) cognitive dysfunction, rather than objective cognitive dysfunction as measured through neuropsychological tests. The relationship between subjective and objective cognitive dysfunction is controversial; a 2012 study showed that while depressed patients reported both subjective and objective cognitive dysfunction, these measures were not correlated (Svendsen et al., 2012) . This lack of correlation was also noted at the time of treatment initiation in a recent analysis of objective and subjective measures of cognitive dysfunction (Olsen et al., 2015) . Nevertheless, two months after treatment initiation, subjective and objective measures of cognitive dysfunction were correlated, although changes in subjective measures of cognition and severity of depression were more tightly correlated than changes in subjective and objective measures of cognition. Subjective cognitive dysfunction may be influenced by a patient's mood symptoms, especially when considering its evolution over time, and thus may not accurately reflect the true extent of objective cognitive dysfunction. As such, both objective and subjective measures of cognitive dysfunction provide unique, complementary information and should be assessed by clinicians. The merit of the current study, despite this limitation, is in evaluating the importance of cognitive impairment from the perspective of the patient and in demonstrating the impact of perceived cognitive dysfunction on functional disability and productivity, regardless of the severity of depression.
A further limitation of the study is the recruitment only of patients who were initiating a new anti-depressant monotherapy, which may somewhat limit the generalisability of the present study results to the whole MDD population in South Korea. In addition, patients' occupations and job-related stress levels were not captured, which may have limited the analysis on potential mechanisms for associations with work impairment. (0-25, 26-29, 30-34, 35-60) 0.022 Results of the present study add to the existing evidence base on the substantial burden of MDD on patients, and confirm and characterise the burden specifically in the South Korean population. A lower quality of life was associated with worse depression severity and greater perceived cognitive dysfunction. Cognitive and depressive symptoms in MDD contribute to impaired functional abilities and work productivity, particularly presenteeism. More specifically, greater functional disability and impairment in daily activities were found to be associated with more severe depression and worse perceived cognitive function. Interestingly, worse perceived cognitive dysfunction was associated with greater impairment in work productivity (specifically, higher presenteeism and greater overall work productivity loss), irrespective of depression severity. This highlights the importance of recognising perceived cognitive dysfunction in routine practice, in which the usual goal of MDD treatment is functional recovery beyond remission of clinical depressive symptoms.
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